Results 81 to 90 of about 3,103 (172)

Unplanned pregnancies following the introduction of elexacaftor/tezacaftor/ivacaftor therapy in women with cystic fibrosis

, 2023
Cystic fibrosis (CF) causes infertility and subfertility due to various factors, including altered cervical mucus, delayed puberty, and hormonal imbalances.
Gramegna, Andrea, Daccò, Valeria, Blasi, Francesco Arturo, Alicandro, Gianfranco, Trespidi, Laura   +4 more
core   +1 more source

Corrigendum: Elexacaftor-Tezacaftor-Ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-Score

Frontiers in Pharmacology, 2023
Jochen G. Mainz, Jochen G. Mainz, Carlos Zagoya, Louise Polte, Lutz Naehrlich, Lutz Naehrlich, Lenny Sasse, Olaf Eickmeier, Christina Smaczny, Anton Barucha, Lilith Bechinger, Franziska Duckstein, Ludwik Kurzidim, Ludwik Kurzidim, Patience Eschenhagen, Laura Caley, Daniel Peckham, Daniel Peckham, Carsten Schwarz   +18 more
doaj   +1 more source

Rethinking hyperbilirubinemia: Gilbert syndrome in children with cystic fibrosis, a case report

Respiratory Medicine Case Reports
Cystic Fibrosis leads to liver complications, including cystic fibrosis liver disease but hyperbilirubinemia in CF patients on CFTR modulators is less understood.
Yara Salameh, John Lyles, Shatha Yousef
doaj   +1 more source

sj-docx-1-smo-10.1177_20503121231225874 – Supplemental material for Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials

Supplemental material, sj-docx-1-smo-10.1177_20503121231225874 for Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials by Rong He, Fei Lin, Zehui Deng and Bin Yu in SAGE Open ...
Bin Yu (14464), Rong He (25641), Fei Lin (156666), Zehui Deng (17815804)   +3 more
core   +1 more source

Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats [PDF]

Introduction:Phe508del is the most common cystic fibrosis transmembrane conductance regulator (CFTR) gene variant that results in the recessive genetic disorder cystic fibrosis (CF). The recent development of highly effective CFTR modulator therapies has
Patricia Cmielewski, Martin Donnelley, Ronan Smith, Piraveen Pirakalathanan, Alexandra McCarron, Nina Eikelis, Elena Schneider-Futschik, David Parsons, Nicole Reyne   +8 more
core   +2 more sources

Extent of foetal exposure to maternal elexacaftor/tezacaftor/ivacaftor during pregnancy

BACKGROUND AND PURPOSE: Cystic fibrosis (CF) patients are living longer and healthier due to improved treatments, e.g. cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy elexacaftor/tezacaftor/ivacaftor (ETI), with treatment ...
Donnelley, M, Habgood, MD, Li, D, Schneider-Futschik, EK, Parsons, D   +4 more
core   +2 more sources

The long-term effect of elexacaftor/tezacaftor/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study

BMC Pulmonary Medicine
Background Physical activity is a crucial demand on cystic fibrosis treatment management. The highest value of oxygen uptake (VO2peak) is an appropriate tool to evaluate the physical activity in these patients.
Nela Stastna, Lenka Hrabovska, Pavel Homolka, Lukas Homola, Michal Svoboda, Kristian Brat, Libor Fila   +6 more
doaj   +1 more source

Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators

Frontiers in Pharmacology
IntroductionCystic Fibrosis (CF) is a genetic disease due to loss-of-function mutations of the CFTR channel. F508del is the most frequent mutation (70% of alleles in Italy), while other mutations have much lower frequency.
Valeria Tomati, Valeria Capurro, Emanuela Pesce, Cristina Pastorino, Elvira Sondo, Mariateresa Lena, Mariateresa Lena, Anna Borrelli, Federico Cresta, Stefano Pantano, Francesca Collini, Pietro Ripani, Vito Terlizzi, Cristina Fevola, Stefano Costa, Maria Cristina Lucanto, Federico Zara, Federico Zara, Tiziano Bandiera, Renata Bocciardi, Renata Bocciardi, Carlo Castellani, Luis J. V. Galietta, Nicoletta Pedemonte   +23 more
doaj   +1 more source

Effets indésirables de l’association tezacaftor/ivacaftor/elexacaftor pouvant mener à un arrêt de traitement: à propos d’une série de 10 cas

International audienceIntroduction: Cystic fibrosis transmembrane regulator (CFTR) channel modulators (ivacaftor, lumacaftor, tezacaftor and elexacaftor) represent a major advance in the management of cystic fibrosis.
Triquet, Louise, Mercerolle, Marion, Polard, Elisabeth, Osmont, Marie-Noëlle, Bacle, Astrid, Blaisonneau, Elora, Belleguic, Chantal, Le Daré, Brendan   +7 more
core   +1 more source

Effect of hypoxia on Cystic Fibrosis Transmembrane conductance Regulator channel corrected by Elexacaftor/Tezacaftor/Ivacaftor

International audienceThe accumulation of mucus resulting from the obstruction of bronchi of cystic fibrosis (CF) patients, induces a reduction of the oxygen (O2) pressure and produces a hypoxic environment for the epithelial cells of the lungs.
Colas, Jenny, Carrez, Thomas, Mirval, Sandra, Coraux, Christelle, Barrault, Christine, Vandebrouck, Clarisse, Sage, Edouard, Pascarel, Khilian, Becq, Frédéric   +8 more
core   +1 more source